TRT Jatenzo denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for trt jatenzo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Jatenzo as Experimental

An "experimental or investigational" denial on Jatenzo (testosterone undecanoate oral capsules) is a significant but appealable determination. Jatenzo holds FDA approval for specific indications in adult males, which is a strong basis for appeal — FDA approval is the primary standard most plans use to distinguish established from experimental therapy. Aetna's experimental designation typically arises when the plan's medical policy has not been updated to reflect current FDA status, when coverage criteria require additional clinical evidence, or when the prescribed use is judged to fall outside the approved indication.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File within 180 days of the denial. Aetna must respond within 30 days (30 days urgent concurrent; 72 hours expedited).
• External review: After a final internal denial, escalate to an independent review organization within approximately four months. The IRO's decision is binding. Experimental-designation denials are among the most frequently overturned at external review when FDA approval is documented.
• Expedited track: Request expedited review if delay is medically harmful.

## The Core Rebuttal: FDA Approval

The foundation of this appeal is the FDA-approved prescribing label for Jatenzo. Your appeal letter should:

1. Cite FDA approval status directly — attach or reference the current FDA label showing the approved indication. 2. Demonstrate your use is on-label — your prescriber's letter must confirm that the prescribed use aligns precisely with the FDA-approved indication, not an off-label application. 3. Reference professional society guidance — the prescriber should note that applicable guidelines from the Endocrine Society recognize oral testosterone undecanoate as an established treatment option, without citing specific numbers. 4. Address Aetna's specific policy language — obtain Aetna's medical policy on testosterone products and respond to every criterion used to classify the therapy as experimental.

## What to Gather

1. FDA prescribing label for Jatenzo — current label with indication section highlighted. 2. Prescriber medical-necessity and rebuttal letter — confirms on-label use, references FDA approval, and cites the relevant Endocrine Society guideline. 3. Confirmed diagnosis documentation — lab-confirmed hypogonadism consistent with the FDA-approved indication. 4. Aetna's experimental-use policy — identify and respond to every stated criterion for the experimental designation. 5. Published peer-reviewed literature — your prescriber may attach key references supporting oral testosterone undecanoate as established therapy, without citing specific statistics.

## Criteria-Mapping Structure

| Aetna Experimental Criterion | Your Rebuttal Evidence | |---|---| | Lacks FDA approval | FDA label — approved indication (attached) | | Use is off-label | Prescriber letter confirming on-label indication | | Inadequate clinical evidence | Peer-reviewed literature references, guideline citation | | Not standard of care | Endocrine Society guideline reference |